Your browser doesn't support javascript.
loading
RNA Interference against ATP as a Gene Therapy Approach for Prostate Cancer.
Chen, Shuangya; Ma, Jisheng; Xiao, Yunbei; Zhou, Dongyan; He, Ping; Chen, Yajing; Zheng, Xiaolu; Lin, Hui; Qiu, Feng; Yuan, Yuying; Zhong, Jiaben; Li, Xiaokun; Pan, Xuebo; Fang, Zhiyuan; Wang, Cong.
Afiliação
  • Chen S; School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325030, China.
  • Ma J; School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325030, China.
  • Xiao Y; Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325030, China.
  • Zhou D; School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325030, China.
  • He P; School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325030, China.
  • Chen Y; School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325030, China.
  • Zheng X; School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325030, China.
  • Lin H; Pharmaceutical Department, Jinhua Central Hospital, Jinhua, Zhejiang 321000, China.
  • Qiu F; School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325030, China.
  • Yuan Y; School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325030, China.
  • Zhong J; School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325030, China.
  • Li X; School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, Guangdong 510006, China.
  • Pan X; School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325030, China.
  • Fang Z; School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325030, China.
  • Wang C; School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, Guangdong 510006, China.
Mol Pharm ; 20(10): 5214-5225, 2023 10 02.
Article em En | MEDLINE | ID: mdl-37733628
ABSTRACT
Chemotherapeutic agents targeting energy metabolism have not achieved satisfactory results in different types of tumors. Herein, we developed an RNA interference (RNAi) method against adenosine triphosphate (ATP) by constructing an interfering plasmid-expressing ATP-binding RNA aptamer, which notably inhibited the growth of prostate cancer cells through diminishing the availability of cytoplasmic ATP and impairing the homeostasis of energy metabolism, and both glycolysis and oxidative phosphorylation were suppressed after RNAi treatment. Further identifying the mechanism underlying the effects of ATP aptamer, we surprisingly found that it markedly reduced the activity of membrane ionic channels and membrane potential which led to the dysfunction of mitochondria, such as the decrease of mitochondrial number, reduction in the respiration rate, and decline of mitochondrial membrane potential and ATP production. Meanwhile, the shortage of ATP impeded the formation of lamellipodia that are essential for the movement of cells, consequently resulting in a significant reduction of cell migration. Both the downregulation of the phosphorylation of AMP-activated protein kinase (AMPK) and endoplasmic reticulum kinase (ERK) and diminishing of lamellipodium formation led to cell apoptosis as well as the inhibition of angiogenesis and invasion. In conclusion, as the first RNAi modality targeting the blocking of ATP consumption, the present method can disturb the respiratory chain and ATP pool, which provides a novel regime for tumor therapies..
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Trifosfato de Adenosina Limite: Humans / Male Idioma: En Revista: Mol Pharm Assunto da revista: BIOLOGIA MOLECULAR / FARMACIA / FARMACOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Trifosfato de Adenosina Limite: Humans / Male Idioma: En Revista: Mol Pharm Assunto da revista: BIOLOGIA MOLECULAR / FARMACIA / FARMACOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China